Second-largest penalties ever for a pharmaceutical company
- Endo Health Solutions ordered to pay $1.54 billion in opioid criminal case
- Second-largest criminal penalties ever levied against a pharmaceutical company
- Endo pleaded guilty to selling misbranded drugs
- Company admitted to touting false safety characteristics of its opioid
- Endo will pay $1.09 billion in criminal fines and $450 million in criminal forfeiture
- Government to receive up to $464.9 million over 10 years
- Endo Health Solutions won’t emerge from bankruptcy
Endo Health Solutions has been ordered to pay over $1.5 billion in a criminal case related to its role in the opioid epidemic. This marks the second-largest criminal penalties ever levied against a pharmaceutical company, with the largest penalties being in the case of Purdue Pharma. Endo pleaded guilty to one misdemeanor count of selling misbranded drugs, admitting that certain sales representatives touted false safety characteristics of its opioid Opana. The company will pay $1.09 billion in criminal fines and $450 million in criminal forfeiture. Additionally, the government will receive up to $464.9 million over 10 years. Despite the settlements, Endo Health Solutions will not emerge from bankruptcy.
Factuality Level: 9
Factuality Justification: The article provides a detailed account of the legal case against Endo Health Solutions, including the charges, penalties, and agreements reached. The information is presented in a straightforward manner without any sensationalism or bias. The article sticks to the facts and does not include any irrelevant information or personal opinions.
Noise Level: 3
Noise Justification: The article provides relevant information about Endo Health Solutions being ordered to pay over $1.5 billion in a criminal case related to the opioid epidemic. It includes details about the charges, fines, and the company’s bankruptcy case settlement. The article stays on topic and supports its claims with specific examples and figures. However, it lacks in-depth analysis, antifragility considerations, and accountability of powerful people, which prevents it from scoring higher.
Financial Relevance: Yes
Financial Markets Impacted: The news article pertains to the pharmaceutical industry and the financial impact on Endo Health Solutions.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The news article discusses the criminal case against Endo Health Solutions related to its role in the opioid epidemic. While it is a significant financial penalty, there is no mention of an extreme event.
Public Companies: Endo Health Solutions (N/A), Purdue Pharma (N/A)
Key People: Ben Glickman (Author)
www.marketwatch.com 
